# Heart Failure and Atrial Fibrillation in Women: Pathophysiological Links, Clinical Challenges, and Therapeutic Perspectives

**Authors:** Luminiţa-Bianca Grosu, Camelia Cristina Diaconu, Laura Gabriela Gavril

PMC · DOI: 10.3390/medicina62020261 · 2026-01-26

## TL;DR

This paper reviews how heart failure and atrial fibrillation affect women differently, focusing on their pathophysiology, treatment, and outcomes.

## Contribution

The paper provides a narrative review highlighting sex-related differences in the treatment and prognosis of heart failure and atrial fibrillation in women.

## Key findings

- Women with heart failure and atrial fibrillation tend to be older at diagnosis and have more comorbidities.
- Women are less likely to receive rhythm control strategies and ablation compared to men.
- Sex-related differences in pathophysiology and treatment impact clinical outcomes and quality of life in women.

## Abstract

Background and Objectives: The prevalence of heart failure and atrial fibrillation is increasing because of population aging. There are important sex-related differences in the epidemiology, pathophysiology, treatment, and prognosis of patients with both heart failure and atrial fibrillation. While the overall lifetime risk of both diseases is similar between women and men, women tend to be older when diagnosed and to have more comorbidities. Materials and Methods: A narrative review was conducted by analyzing studies published across databases such as PubMed, SCOPUS, Web of Science, and Google Scholar. The review focused on research about sex-related differences in patients with heart failure and atrial fibrillation, emphasizing the peculiarities in women regarding drug treatment and prognosis after cardiac device implantation. Results: Current evidence highlights the sex-related differences in patients with both heart failure and atrial fibrillation regarding pathophysiology, clinical manifestations, and echocardiographic findings. There are also data regarding possible sex-related differences in mortality and therapy, as women tend to have longer hospital stays, but there are fewer reevaluations after discharge. Conclusions: Women with both atrial fibrillation and heart failure are at increased risk of stroke and other adverse outcomes that negatively affect their quality of life. Females with atrial fibrillation and heart failure tend to be treated less with rhythm control strategies and ablation, which may have a great impact on symptom burden in women compared to men.

## Linked entities

- **Diseases:** heart failure (MONDO:0005252), atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Genes:** ESR2 (estrogen receptor 2) [NCBI Gene 2100] {aka ER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2}, GPER1 (G protein-coupled estrogen receptor 1) [NCBI Gene 2852] {aka CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}
- **Diseases:** injury to (MESH:D014947), inflammation (MESH:D007249), atrial fibrosis (MESH:D005355), dyslipidemia (MESH:D050171), coronary heart disease (MESH:D003327), dyspnea (MESH:D004417), responses (MESH:D018746), ischemic (MESH:D002545), Endothelial dysfunction (MESH:D014652), weakness (MESH:D018908), diabetes (MESH:D003920), anxiety (MESH:D001007), Diastolic dysfunction (MESH:D018487), autoimmune diseases (MESH:D001327), arrhythmia (MESH:D001145), hemorrhage (MESH:D006470), obesity (MESH:D009765), chest pain (MESH:D002637), fatigue (MESH:D005221), Stroke (MESH:D020521), sudden cardiac death (MESH:D016757), ischemia (MESH:D007511), cardio-renal-metabolic syndrome (MESH:D059347), microvascular (MESH:D017566), arterial stiffness (MESH:C566112), hypertension (MESH:D006973), LV concentric hypertrophy (MESH:D017379), death (MESH:D003643), myocardial infarction (MESH:D009203), cardiovascular death (MESH:D002318), congestion (MESH:D002311), infection (MESH:D007239), Atrial Fibrillation (MESH:D001281), hypertrophy (MESH:D006984), pneumothorax (MESH:D011030), Acute Infarction (MESH:D056989), insulin resistance (MESH:D007333), dizziness (MESH:D004244), torsades de pointes (MESH:D016171), ion channel dysfunction (MESH:D020513), Heart Failure (MESH:D006333), depression (MESH:D003866), tricuspid regurgitation (MESH:D014262), atrial enlargement (MESH:D006332), thromboembolic (MESH:D013923), LV dilation (MESH:D020257), mycotic infections (MESH:D015821), high (MESH:D008228), palpitations (MESH:D006331), HFrEF (MESH:D054143), HFmrEF (MESH:D054144)
- **Chemicals:** E2 (MESH:D004958), cortisol (MESH:D006854), aldosterone (MESH:D000450), testosterone (MESH:D013739), progesterone (MESH:D011374), erythromycin (MESH:D004917), ibutilide (MESH:C067192), ARNI (-), catecholamines (MESH:D002395), natriuretic peptides (MESH:D045265), terfenadine (MESH:D016593), Ramipril (MESH:D017257), quinidine (MESH:D011802), sotalol (MESH:D013015), amiodarone (MESH:D000638), spironolactone (MESH:D013148), steroids (MESH:D013256), disopyramide (MESH:D004206), Sacubitril (MESH:C000717211), digoxin (MESH:D004077), metoprolol (MESH:D008790), alcohol (MESH:D000438), Valsartan (MESH:D000068756), reactive oxygen species (MESH:D017382), calcium (MESH:D002118)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942200/full.md

---
Source: https://tomesphere.com/paper/PMC12942200